Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-090747
Filing Date
2024-08-05
Accepted
2024-08-05 16:10:38
Documents
69
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q pstx-20240630.htm   iXBRL 10-Q 2149890
2 EX-10.1 pstx-ex10_1.htm EX-10.1 727632
3 EX-31.1 pstx-ex31_1.htm EX-31.1 12865
4 EX-31.2 pstx-ex31_2.htm EX-31.2 12847
5 EX-32.1 pstx-ex32_1.htm EX-32.1 8209
6 EX-32.2 pstx-ex32_2.htm EX-32.2 8232
7 GRAPHIC img78622461_0.jpg GRAPHIC 8513
8 GRAPHIC img78622461_1.jpg GRAPHIC 18104
  Complete submission text file 0000950170-24-090747.txt   8709340

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT pstx-20240630.xsd EX-101.SCH 1157400
72 EXTRACTED XBRL INSTANCE DOCUMENT pstx-20240630_htm.xml XML 1105968
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

EIN.: 472846548 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39376 | Film No.: 241174855
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)